Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Observation.
- Who it may be relevant to
- Registry conditions: Intraductal Papillary Mucinous Neoplasm. Basic parameters: 0 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Prospective, Open Large Cohort Study of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
Overview
This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.
Detailed description
This prospective study was designed to explore biomarkers for detecting early carcinogenesis of IPMN. This study intends to prospectively and continuously enroll IPMN patients, and regularly collect biological samples including blood, urine, feces and saliva. We aimed to detect biomarkers which can predict the carcinogenesis of IPMN by multi-omics. The primary endpoint is the predictive accuracy of biomarkers for IPMN malignant transformation. The probability of IPMN malignant transformation , rates of surgical resection and survival after surgery are secondary endpoints.
Interventions
- Other Observation
This is an observational study.
Primary outcome measures
- The accuracy of IPMN malignant transformation [Time frame: Up to 10 years]
Secondary outcome measures (3)
- the probability of IPMN malignant transformation [Time frame: Up to 10 years]
- rates of surgical resection [Time frame: Up to 10 years]
- survival after surgery [Time frame: Up to 10-15 years]
Eligibility criteria
Inclusion criteria
- clinically diagnosed as IPMN;
- without other malignant tumor;
- agree to sign informed consent.
Exclusion criteria
- with mental disorders which can affect cognition and cooperation;
- with serious blood diseases or taking drugs that can affect peripheral blood
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- the First Affiliated Hospital, School of Medicine, Zhejiang University — Hangzhou
Identifiers
NCT: NCT05433935 · PCIPMN